GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gossamer Bio Inc.
Shares of Gossamer Bio, a biotech company focused on treating immune diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological and inflammatory diseases. We have classified it in the Pharma: Immunology segment. The chart below shows how investors view the prospects of this broad and competitive biotech segment.
Broad Market Index - GURU.Markets
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological and inflammatory diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
GOSS - Daily change in the company's share price Gossamer Bio Inc.
Shares of Gossamer Bio, a biopharmaceutical company, are highly volatile. change_co tracks investor reactions to news about clinical trials of its drugs. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Gossamer Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with GOSS, which focuses on immune disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Gossamer is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess the performance of Gossamer's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gossamer Bio Inc.
Gossamer is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Gossamer Bio, Inc. is a clinical-stage biotech company focused on developing drugs for the treatment of immunological and inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gossamer Bio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gossamer Bio Inc.
BlackSky, a company that provides satellite imagery and real-time analytics services, primarily for the defense and intelligence sectors, has monthly fluctuations reflecting the receipt of new government contracts, which are its primary source of revenue.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Gossamer Bio is a biotech company focused on immunology and inflammatory diseases. Its sector is eagerly awaiting clinical trial results. The industry trend chart shows the overall level of investor optimism or skepticism regarding the research-intensive developments on which Gossamer's future and its share price depend entirely.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for immunological, inflammatory, and oncological diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to demonstrate how scientific news has driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gossamer Bio Inc.
Gossamer Bio is a biotech company focused on immunology and inflammatory diseases. Its weekly stock price is volatile and dependent on clinical trial news, which is typical for companies in the R&D stage.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Gossamer Bio is a biotech company focused on immunology. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart below shows how news about clinical trials of its drugs drives share prices independently of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Gossamer, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
GOSS - Market capitalization of the company Gossamer Bio Inc.
Gossamer Bio's market capitalization tells the story of the search for new drugs to treat immune and inflammatory diseases. This clinical-stage biotech's stock chart reflects the roller coaster of trial results. Its volatility illustrates how a single piece of news can dramatically alter the company's prospects.
GOSS - Share of the company's market capitalization Gossamer Bio Inc. within the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company developing novel treatments for immunological, inflammatory, and oncological diseases. Its sector share reflects the potential of its research pipeline. The chart below is a barometer of the market's confidence in its scientific developments.
Market capitalization of the market segment - Pharma immune
Gossamer Bio is a biopharmaceutical company developing drugs to treat immunological and inflammatory diseases. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. It reflects the high risks and potential of this field, where success in clinical trials could lead to a blockbuster.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents scientific research in the field of immunology. Gossamer Bio develops drugs to treat allergic and inflammatory diseases. Its volatile market cap reflects the ups and downs of clinical trials. It's a visualization of the risky path from a lab idea to a drug on the shelf.
Book value capitalization of the company, segment and market as a whole
GOSS - Book value capitalization of the company Gossamer Bio Inc.
Gossamer Bio's foundation is its financial reserves and intellectual property for drugs for the treatment of immunological and inflammatory diseases. This constitutes its scientific and financial capital. The chart shows how this biotech company manages its "budget" for clinical trials and drug development.
GOSS - Share of the company's book capitalization Gossamer Bio Inc. within the market segment - Pharma immune
Gossamer Bio is a biotech company developing drugs for immune and inflammatory diseases. Its assets are patents and R&D, not manufacturing plants. The chart shows a minimal share of physical assets, which is typical for an R&D company.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat immune diseases, like Gossamer Bio's, is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Gossamer Bio's assets are not product lines, but capital and intellectual property focused on developing new drugs for the treatment of immune and inflammatory diseases. These assets represent the financial resources available for clinical trials. The chart illustrates the scale of this biotech company relative to the pharmaceutical industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gossamer Bio Inc.
For Gossamer Bio, which develops drugs for immune diseases, market capitalization is a bet on the success of its clinical trials. The ratio to book value (its equity) reflects the degree of confidence investors have in its scientific approach and team.
Market to book capitalization ratio in a market segment - Pharma immune
Gossamer Bio is a biotech company developing drugs to treat immune diseases. Its high market valuation on this chart, despite its modest tangible assets, is a classic example of biotech investors buying into scientific potential and the hope of a future blockbuster.
Market to book capitalization ratio for the market as a whole
Gossamer Bio is a clinical-stage biotech company developing drugs to treat immune and inflammatory diseases. Its valuation is dependent on clinical trial results. This biotech metric demonstrates how expectations of future success or failure can drive sharp fluctuations in market value, with little correlation to book value.
Debts of the company, segment and market as a whole
GOSS - Company debts Gossamer Bio Inc.
Gossamer Bio, a biotech company focused on immunology, uses raised capital to fund its clinical programs. For a company without revenue, access to debt and equity markets is a matter of survival and the ability to bring its scientific ideas to fruition. This chart shows the cost of these efforts.
Market segment debts - Pharma immune
Gossamer Bio is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. This chart shows how the company funds its expensive R&D programs by raising capital from investors to advance its drug candidates through various phases of clinical trials, as is standard in the industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs to treat immunological and inflammatory diseases. Clinical trials are a lengthy, expensive, and risky process. This chart shows the company's reliance on debt to fund its research, reflecting the high stakes of the biotech race.
Market segment debt to market segment book capitalization - Pharma immune
Gossamer Bio is a biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Clinical trials in this area are complex and expensive. This chart shows how the company finances its research and development, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Gossamer Bio is a biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Clinical trials are a lengthy and expensive process. How heavily does the company rely on debt? This chart of total market debt allows investors to assess its financial strength as it works to develop a new drug.
P/E of the company, segment and market as a whole
P/E - Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immune and inflammatory diseases. This chart shows how investors value its scientific developments. The valuation is volatile and depends on news about the clinical trials of its candidates.
P/E of the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company specializing in the development of new drugs for the treatment of immune, inflammatory, and oncological diseases. This chart shows the average valuation for the sector, providing investors with context for assessing Gossamer Bio's scientific pipeline and potential.
P/E of the market as a whole
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Valuing such companies is a bet on the success of clinical trials. Does comparing this chart reveal the extent to which Gossamer investors are ignoring the broader market picture, betting solely on its scientific potential?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gossamer Bio Inc.
Gossamer Bio is a biotechnology company developing drugs to treat immune and inflammatory diseases, particularly pulmonary arterial hypertension. This chart reflects market expectations regarding the success of its clinical programs. Future revenue depends on regulatory approvals and the commercial potential of its drugs.
%20P%2FE%20Gossamer%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gossamer-Bio-Inc.&v=1772326480718 "Chart of the company's future (projected) P/E Gossamer Bio Inc.")
Future (projected) P/E of the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of immune and inflammatory diseases, including asthma and pulmonary hypertension. The chart shows industry forecasts, allowing investors to compare their confidence in Gossamer's scientific platform with expectations for other companies in these therapeutic areas.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772326480720 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Gossamer Bio, Inc. is a biopharmaceutical company focused on immunology and inflammatory diseases. Its valuation is based on the potential of its scientific developments. This market sentiment chart shows how willing investors are to invest in innovative but not yet profitable medical companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772326480722 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company developing drugs to treat immune and inflammatory diseases. With no products on the market, its financial results represent a net loss from R&D. This chart shows the cost of research and development required to create new drugs in complex areas of medicine.
Profit of companies in the market segment - Pharma immune
Gossamer Bio is a biotechnology company developing new drugs for the treatment of immunological and inflammatory diseases. This chart, reflecting the profitability of the pharmaceutical sector, is important to them as an indicator of the investment climate. Positive dynamics in the industry help them attract funding for clinical trials of their innovative molecules.
Overall market profit
Gossamer Bio is a biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Like many companies in clinical trials, its value depends on scientific results and investor sentiment. Growing market returns, as shown in this chart, are typically accompanied by increased risk appetite, making it easier for biotech companies to raise capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gossamer Bio Inc.
Gossamer Bio is a biotech company developing drugs to treat immunological and inflammatory diseases, including asthma. Its success depends on the results of clinical trials. This chart shows analyst expectations regarding the potential of their lead candidates and the likelihood of their commercialization in major pharmaceutical markets.
%20profit%20of%20the%20company%20Gossamer%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gossamer-Bio-Inc.&v=1772326480729 "Graph of future (projected) profit of the company Gossamer Bio Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Gossamer Bio is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. Its future depends on the success of clinical trials. This biotech chart reflects overall investor sentiment and their expectations for companies developing new classes of drugs for complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772326480730 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Gossamer Bio, a biopharmaceutical company, focuses on immunology and inflammatory diseases. Its market capitalization depends on the success of its developments. However, the overall profit forecast, illustrated by this chart, influences investors' risk appetite, which is critical for funding long-term and expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772326480731 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gossamer Bio Inc.
Gossamer Bio is a biotech company focused on drug discovery and development in immunology, inflammation, and oncology. As the company is in the clinical stage, this chart is key. It shows how investors evaluate the scientific potential and future sales of its developments, betting on breakthroughs in the treatment of complex diseases.
P/S market segment - Pharma immune
Gossamer Bio is a biopharmaceutical company developing novel treatments for immune and inflammatory diseases. The company's valuation is based on the potential of its clinical programs. This chart, which displays the average valuation in the biotech industry, helps investors understand how expectations for Gossamer's pipeline align with industry sentiment.
P/S of the market as a whole
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing new drugs in immunology, inflammation, and oncology. This chart, which reflects revenue estimates for real businesses, highlights that Gossamer Bio's value reflects investors' bet on the success of its scientific research and the potential of its drugs to become new standards of care.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biotechnology company focused on developing drugs for the treatment of immune and inflammatory diseases. Its valuation is based on future potential. This chart reflects investor expectations for successful clinical trials and the commercialization of innovative drugs for a large patient population.
%20P%2FS%20Gossamer%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gossamer-Bio-Inc.&v=1772326480739 "The graph of the company's future (projected) P/S Gossamer Bio Inc.")
Future (projected) P/S of the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of new drugs for the treatment of immunological and inflammatory diseases. This chart reflects average revenue expectations in the biotech sector. It allows investors to assess how highly the market values the scientific potential of Gossamer Bio's portfolio.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772326480742 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Gossamer Bio is a biotech company developing new drugs to treat immune and inflammatory diseases. This chart shows overall market revenue forecasts. Gossamer's success in clinical trials could lead to new treatments for a wide range of patients, fueling investor confidence in the future growth of the entire industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772326480745 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gossamer Bio Inc.
This chart illustrates the revenue of Gossamer Bio, a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological and inflammatory diseases. At this stage, its revenue is generated primarily from collaboration fees with other companies, reflecting research progress rather than drug sales.
Sales of companies in the market segment - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing new drugs in immunology, inflammation, and oncology. This chart reflects revenue in the pharmaceutical sector. Although the company does not yet have commercial products, its innovative developments are aimed at creating breakthrough treatments for patients with serious diseases.
Overall market sales
Gossamer Bio is a biopharmaceutical company focused on immunology and inflammatory diseases. Its growth depends on the results of clinical trials and partnerships. The overall economic situation, reflected in this chart, impacts the availability of capital to fund long-term research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gossamer Bio Inc.
Gossamer Bio is a biotechnology company developing drugs to treat immune and inflammatory diseases. Its revenue projections are based on expectations of clinical trial success. The chart reflects analysts' confidence in the commercial potential of its candidate molecules.
%20sales%20of%20the%20company%20Gossamer%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gossamer-Bio-Inc.&v=1772326480760 "Schedule of future (projected) sales of the company Gossamer Bio Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Gossamer Bio is a biopharmaceutical company focused on the discovery and development of new drugs in immunology, inflammation, and oncology. The company has a diversified pipeline of candidates at various stages of development. This chart shows the outlook for the entire pharmaceutical market, where Gossamer strives to offer breakthrough treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772326480765 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Gossamer Bio is a biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Its market capitalization depends on investor expectations regarding the success of clinical trials. This chart reflects the overall market risk appetite, but Gossamer's key driver is the scientific data on its molecules, which could change treatment approaches.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772326480774 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gossamer Bio Inc.
Gossamer Bio is a biotech company developing new drugs to treat immune and inflammatory diseases. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in research to develop drugs to treat conditions such as asthma and inflammatory bowel disease.
Market segment marginality - Pharma immune
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for immunological, inflammatory, and oncological diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential of their broad pipeline of drug candidates.
Market marginality as a whole
Gossamer Bio is a biotechnology company developing new drugs in immunology, inflammation, and oncology. Their goal is to create treatments for patients with unmet medical needs. This overall profitability curve is irrelevant to them. Their success depends solely on the scientific data obtained during clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biotech company specializing in immunology and inflammatory diseases. Its team consists of scientists and clinical development experts. The growth on this chart indicates that its drug candidates are advancing into later, more resource-intensive phases of testing.
Share of the company's employees Gossamer Bio Inc. within the market segment - Pharma immune
Gossamer Bio is a biopharmaceutical company focused on developing drugs to treat immune and inflammatory diseases. This chart shows its share of the total number of researchers in this field. The growth in this figure indicates progress in clinical trials and the expansion of the scientific team working on new therapeutic solutions.
Number of employees in the market segment - Pharma immune
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing new drugs in immunology, inflammation, and oncology. This chart shows the dynamics of employment in the R&D sector. Fluctuations in scientific personnel often reflect progress or setbacks in clinical trials, which are a key factor for such companies.
Number of employees in the market as a whole
Gossamer Bio is a biopharmaceutical company developing drugs to treat immunological and inflammatory diseases, including asthma and allergies. Its goal is to create best-in-class medicines. This chart shows how Gossamer's innovations in chronic disease treatments are creating demand for scientists, physicians, and clinical trial specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gossamer Bio Inc. (GOSS)
Gossamer Bio is a biotech company specializing in immunology and inflammatory diseases. This chart is a prime example of intellectual capital valuation. The company's value is based solely on its research potential and development pipeline. The chart shows how highly the market values the future value of these innovative treatments per scientist.
%20of%20the%20company%20Gossamer%20Bio%20Inc.%20(GOSS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gossamer-Bio-Inc.-GOSS&v=1772326480794 "Chart of market capitalization per employee (in thousands of dollars) of the company Gossamer Bio Inc. (GOSS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Gossamer Bio is a biotech company focused on developing drugs to treat immune and inflammatory diseases. Its value is based on its research potential. This chart demonstrates the company's high valuation of intellectual capital and future prospects based on its small staff of highly qualified scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772326480796 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Gossamer Bio is a biopharmaceutical company focused on developing drugs to treat immune and inflammatory diseases. The chart reflects the company's valuation at the clinical stage. The company's entire value is derived from the hope for the success of its developments. This indicator demonstrates the value the market places on the work of a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772326480798 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gossamer Bio Inc. (GOSS)
Gossamer Bio is a clinical-stage biotech company specializing in developing drugs for the treatment of immune and inflammatory diseases. This is a science-intensive R&D company. This chart reflects the high stakes: it shows the investment required for each scientist working on a potential breakthrough drug.
%20Chart%20Gossamer%20Bio%20Inc.%20(GOSS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gossamer-Bio-Inc.-GOSS&v=1772326480806 "Company Profit Per Employee (in thousands of dollars) Chart Gossamer Bio Inc. (GOSS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Gossamer Bio (GOSS) is a clinical-stage biotechnology company developing drugs for the treatment of immune and inflammatory diseases. This metric (loss per employee) reflects the high costs of R&D and clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772326480808 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Gossamer Bio is a clinical-stage biotech company specializing in immunology and inflammatory diseases. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per research team leading the development of a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772326480810 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gossamer Bio Inc. (GOSS)
Gossamer Bio is a biopharmaceutical company focused on developing drugs to treat immune and inflammatory diseases. This chart reflects the progress of monetizing its research. Revenue at this stage likely comes from partnerships, and the growth in revenue per employee is an indicator of interest in its research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gossamer-Bio-Inc.-GOSS&v=1772326480812 "Sales chart per company employee Gossamer Bio Inc. (GOSS)")
Sales per employee in the market segment - Pharma immune
Gossamer Bio is a biotech company focused on developing drugs to treat immune and inflammatory diseases. This chart shows how productive their research team is. It measures revenue (likely from partnerships) per researcher, comparing them to other companies in the immunology segment.
Sales per employee for the market as a whole
Gossamer Bio (GOSS) is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of immune and inflammatory diseases. The company currently has no commercial products or revenue. This chart illustrates a classic biotech situation: a team of scientists and researchers focused on R&D, which is an investment in future cash flows.
Short shares by company, segment and market as a whole
Shares shorted by company Gossamer Bio Inc. (GOSS)
Gossamer Bio, Inc. is a biotech company focused on immunology and inflammatory diseases. The company has experienced clinical trial failures. The bearish sentiment shown in this chart reflects investor bets that its remaining pipeline will also fail and the company will be unable to develop a commercial product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gossamer-Bio-Inc.-GOSS&v=1772326480816 "Short Shares Chart for the Company Gossamer Bio Inc. (GOSS)")
Shares shorted by market segment - Pharma immune
Gossamer Bio is a biotech company developing drugs to treat immune and inflammatory diseases. This metric measures pessimism. "Shorts" here represent a bet that their key drug (seralutinib) for treating pulmonary hypertension will fail in clinical trials.
Shares shorted by the overall market
Gossamer Bio is a biotech company working in the field of immunology. Shares of such companies fluctuate between trial press releases. When this chart shows rising general fear, disappointing data or delays are perceived as catastrophic by the market. General pessimism leaves no room for error.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gossamer Bio Inc. (GOSS)
Gossamer Bio (GOSS) is a biotech company focused on developing drugs to treat immunological and inflammatory diseases. Their success is entirely dependent on R&D. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to setbacks or delays, which is typical for biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gossamer-Bio-Inc.-GOSS&v=1772326480820 "RSI 14 indicator chart for the company's stock Gossamer Bio Inc. (GOSS)")
RSI 14 Market Segment - Pharma immune
Gossamer Bio (GOSS) is a biotech company developing drugs to treat immune and inflammatory diseases. The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether GOSS's volatility is a reaction to its trials or simply general hype in the sector.
RSI 14 for the overall market
Gossamer Bio (GOSS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GOSS (Gossamer Bio Inc.)
Gossamer Bio is a biotech company developing drugs for the treatment of immunological and inflammatory diseases. They focus on developing oral (tablet-based) therapies. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GOSS-Gossamer-Bio-Inc.&v=1772326480844 "A chart showing analyst consensus forecasts for the expected stock price. GOSS (Gossamer Bio Inc.)")
The difference between the consensus estimate and the actual stock price GOSS (Gossamer Bio Inc.)
Gossamer Bio is a clinical-stage biotech focused on immunology and inflammation. Its key bet is Seralutinib, a drug for the treatment of pulmonary arterial hypertension (PAH). This is an R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the success of this blockbuster.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GOSS-Gossamer-Bio-Inc.&v=1772326480857 "A chart showing the difference between the consensus forecast and the actual stock price. GOSS (Gossamer Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Gossamer Bio is a biotech company specializing in the development of new drugs (pills) for the treatment of immune and inflammatory diseases, such as pulmonary hypertension. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects experts' confidence in the success of this complex R&D field.
Analysts' consensus forecast for the overall market share price
Gossamer Bio is an R&D biotech focused on immunology (asthma, inflammation). They're burning through cash. This chart, reflecting the economic consensus, is their risk appetite. If the consensus is negative (downturn), investors flee cash-burning, pre-profit biotechs, and capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gossamer Bio Inc.
Gossamer Bio is a clinical-stage biotech focused on treating immune and inflammatory diseases (e.g., asthma, ulcerative colitis). This chart is a pure indicator of biotech expectations. It doesn't reflect current revenue, but rather an aggregate assessment of their scientific data, clinical trial progress, and market confidence in their R&D pipeline.
AKIMA Market Segment Index - Pharma immune
Gossamer (GOSS) is a clinical-stage biotech focused on immunology; the company is developing (after failures) a new candidate (Seralutinib) for the treatment of pulmonary hypertension (PAH). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this risky R&D bet (GOSS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Gossamer Bio is a biopharmaceutical company developing a therapy for pulmonary arterial hypertension (seralutinib). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this late-stage research company stacks up against the broader economic trends affecting the biotech sector.
